US studies bolster CryoLife in knee implant case:
This article was originally published in Clinica
Executive Summary
US studies released last week by the Centers for Disease Control and Prevention (CDC) and the FDA have served to exonerate Atlanta, Georgia-based CryoLife from any possible involvement in the Minnesota knee implant death. Last month, a small cluster of knee implant deaths aroused concern that a common casual link was to blame. In the event, only one patient had been implanted with a CryoLife product. It transpired, as anticipated by CryoLife, that Clostridium sordellii, a rare bacterial infection, was the cause of the death. CryoLife worked with the agencies to identify the cause. Following the findings, the US agencies have decided that no changes to CryoLife's human tissue processing protocols are necessary.
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.